Veracyte Inc (VCYT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Veracyte Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 46.30 $ — 62% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 20.4% passed
- More than 10% revenue growth is expected for the coming year 11.6% passed
- Share count grows by less than 3% a year 4.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 40.5% passed
- Gross margin at 40% or higher and without meaningful erosion 69.6% passed
- Goodwill from acquisitions does not grow faster than revenue 54.6% passed
- Net debt below twice EBITDA 373 m net cash passed
- Operating cash flow covers the profits of the last three years 240 m passed
- Return on capital at 15% or higher, or up versus two years ago 5.5% passed
- Insiders hold at least 10% or are net buyers 0.6% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 26.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 11
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.92 | 1.85 – 1.99 | 592 | 7.9% | 6 |
| 12/31/2027 | 1.93 | 1.74 – 2.11 | 657 | 0.5% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.06 | – | 119 | 20.80 | 4.30 | 25 | 20 |
| 2025: Q1 | 0.09 | – | 115 | 18.20 | 6.20 | 5 | 4 |
| 2025: Q2 | -0.01 | -116.50 | 130 | 13.80 | -0.80 | 34 | 32 |
| 2025: Q3 | 0.24 | 24.30 | 132 | 13.80 | 14.50 | 45 | 42 |
| 2025: Q4 | 0.51 | 690.10 | 141 | 18.50 | 29.30 | 53 | 48 |
| 2026: Q1 | 0.35 | 301.10 | 139 | 21.50 | 20.60 | 35 | 32 |
| 2026: Q2 | 0.31 | 3,200.00 | 150 | 15.40 | 17.00 | 46 | 43 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 65 | -29 | -31 | -1.09 | -28 | 60 | 101 |
| 2017 | 72 | -27 | -31 | -0.91 | -24 | 37 | 79 |
| 2018 | 92 | -22 | -23 | -0.62 | -14 | 80 | 121 |
| 2019 | 120 | -15 | -13 | -0.27 | -3 | 239 | 275 |
| 2020 | 117 | -35 | -35 | -0.66 | -10 | 421 | 457 |
| 2021 | 220 | -82 | -76 | -1.11 | -32 | 1,097 | 1,188 |
| 2022 | 297 | -41 | -37 | -0.51 | 8 | 1,075 | 1,156 |
| 2023 | 361 | -86 | -74 | -1.02 | 44 | 1,044 | 1,115 |
| 2024 | 446 | 16 | 24 | 0.31 | 75 | 1,176 | 1,300 |
| 2025 | 517 | 74 | 66 | 0.82 | 136 | 1,310 | 1,406 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Veracyte, Inc. ist als Diagnostikunternehmen in den USA und international tätig.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 755 |
| Headquarters | South San Francisco, CA |
| Address | 6000 Shoreline Court, 94080 South San Francisco, United States |
| Phone | 650 243 6300 |
| Website | veracyte.com |
| IPO Date | 30. Oct 2013 |
| ISIN | US92337F1075 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Marc A. Stapley | CEO & Director | 1970 |
| Rebecca Chambers | Executive VP & CFO | 1978 |
| Phillip G. Febbo M.D. | Chief Scientific & Medical Officer | 1966 |
| Annie McGuire | Executive VP, General Counsel & Head of Market Access | 1981 |
| John Leite Ph.D. | Global Chief Commercial Officer | 1972 |
| Keith Gligorich Ph.D. | Senior Vice President of Global Operations | – |
| Jonathan Wygant | VP & Chief Accounting Officer | 1971 |
| Kevin Richard Haas Ph.D. | Chief Development and Technology Officer | 1985 |
| Steven French | Senior VP & Chief Information Officer | – |
| Kelly Gura | Director of Investor Relations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.